Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 18Hodgkin Disease 10Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Myelodysplastic Syndromes 6Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Non-Small-Cell Lung 5Waldenstrom Macroglobulinemia 4Neoplasms 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia 4Immunoblastic Lymphadenopathy 4Glioma 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Mycosis Fungoides 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Diffuse Intrinsic Pontine Glioma 3Burkitt Lymphoma 3Solid Tumors 2

Interventions

fluorodopa F 18 4Temozolomide 2Leucovorin 2Fluorouracil 2Everolimus 2Capecitabine 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1vatalanib 1regorafenib 1pentetreotide 1pasireotide 1Thalidomide 1Surgical Procedures, Operative 1Solutions 1Saline Solution 1Panobinostat 1Oxaliplatin 1Octreotide 1Observation 1Irinotecan 1Injections 1High-Energy Shock Waves 1Doxorubicin 1Bortezomib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Insulinoma × Panobinostat × Clear all
NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡